Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCP2TS)

• Drug Name: Nomifensine Drug Info
• Synonyms: Linamiphen; Nomifenison; Nomifensin; Nomifensina; Nomifensinum; Nomiphensine; Nomifensina [INN-Spanish]; Nomifensine [INN:BAN]; Nomifensine maleate(USAN); Nomifensinum [INN-Latin]; D,L-nomifensine; Nomifensine Maleate (1:1); R/S-nomifensine; (+)-Nomifensine; (+)-Nomiphensine; (+-)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; (+-)-Nomifensin; (+-)-Nomifensine; (R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine 2-butenedioate; 2-Methyl-4-phenyl-1,2,3,4-tetrahydro-isoquinolin-8-ylamine; 2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine; 2-methyl-4-phenyl-3,4-dihydro-1H-isoquinolin-8-amine; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolin; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline; 8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline maleate (1:1); 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl; 8-Isoquinolinamine, 1,2,3,4-tetrahydro-2-methyl-4-phenyl-(9CI)

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 4528
  ChEBI ID: CHEMBL273575
  CAS Number: CAS 24526-64-5
  TTD Drug ID: DMCP2TS
  VARIDT Drug ID: DR00944

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[6]
Haloperidol	DM96SE0	Delirium		Approved	[7]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[8]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[9]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[10]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[11]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[12]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[13]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[14]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[15]

Drug(s) Metabolized By Dimethylaniline oxidase 5 (FMO5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[3]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[4]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[16]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[4]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[4]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[17]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[4]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[4]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[18]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[19]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[4]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[20]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[21]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[20]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[23]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[24]
Methysergide	DM1EF73	Migraine	8A80	Approved	[5]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[25]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[26]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[5]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[21]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[27]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[28]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[29]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[4]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[4]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[4]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[4]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[4]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[4]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[4]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Dimethylaniline oxidase 5 (FMO5) Main DME	DEBMX7C	FMO5_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[4]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[4]
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Gene/Protein Processing	[5]
PTB-containing, cubilin and LRP1-interacting protein (PID1)	OT5YJ7FI	PCLI1_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4792).
• [2] Pharmacologically induced, subsecond dopamine transients in the caudate-putamen of the anesthetized rat. Synapse. 2007 Jan;61(1):37-9.
• [3] Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
• [4] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [5] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [6] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [7] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [8] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [9] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [10] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [12] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [13] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [14] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [15] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [16] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [17] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [18] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [19] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [20] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [21] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [22] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [23] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [24] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [25] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [26] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [27] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [28] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [29] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [30] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.